About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00674947

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Lead sponsor: Biogen•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Biogen

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age 18 years or older at the time of informed consent.
•Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists.
•ECOG Performance Status \</= 2.

Exclusion Criteria

•History of keratoconjunctivitis, open or closed angle glaucoma, or "dry eye" disease.
•New York Heart Association (NYHA) Grade II or greater congestive heart failure.
•History of myocardial infarction within 6 months prior to Day 1.
•Presence of \>/= Grade 2 peripheral neuropathy.
•Known presence of central nervous system or brain metastases.
•Prior therapy with a conjugated or unconjugated maytansine derivative.

Related studies

RECRUITINGPhase 1/2

Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more

RECRUITINGPhase 1

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

NCT07042100 · Advanced Solid Tumors

RECRUITINGPhase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

RECRUITINGPhase 1

A Study of SKB107 in Advanced Solid Tumors With Bone Metastases

NCT07087197 · Metastatic Solid Tumors

RECRUITINGPhase 1/2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497 · Locally Advanced / Metastatic Solid Tumors

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 16, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment55

Start dateJun 2008

Last updatedSep 16, 2013

Condition

Locations shown

Research Site

Santa Monica, California

Research Site

Philadelphia, Pennsylvania

Research Site

San Antonio, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2013Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions